Takeda Pharmaceutical Company Limited (TAK) Stock

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for patients with agammaglobulinemia or hypogammaglobulinemia. These conditions are marked by very low or absent antibody levels, leading to a higher risk of serious infections due to primary or secondary immunodeficiency.

Takeda Pharmaceutical provides a strong dividend yield, but its reliability is uncertain because of exchange rate risks and a payout ratio that frequently goes over 100%. Although there is growth in areas like Livtencity and Qdenga, the company's high debt and weak currency make it a risky choice for dividend investors. The drop in the yen's value compared to the dollar greatly affects revenue growth and the stability of dividends for investors in the U.S.

Alloy Therapeutics Inc. has announced a partnership and licensing deal with Takeda Pharmaceutical Company to advance Takeda's unique CAR-T and CAR-NK cell platforms derived from induced pluripotent stem cells. Alloy aims to speed up the development of these innovative technologies. This collaboration highlights Alloy's commitment to making advanced drug discovery tools more accessible.

Masa Takeda, a portfolio manager at Hennessy Japan Fund, appears on CNBC's 'Power Lunch' to share his positive outlook on Japan. He also talks about the potential impact of president-elect Trump's suggested tariffs on Japanese businesses and other related topics.

Takeda Pharmaceutical Company Limited (NYSE:TAK) will hold its Q2 2025 Earnings Call on October 31, 2024, at 6:00 AM ET. The call will feature several key company leaders, including Christophe Weber, the President and CEO, and Milano Furuta, the CFO. Christopher O'Reilly, the Head of Investor Relations, will be the host for the event.

Takeda Pharmaceutical from Japan became profitable again in the second quarter after facing significant losses last year. The company is also making changes to reduce expenses.

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has released its earnings results for the first half of fiscal year 2024, which ended on September 30, 2024, showing strong growth driven by its Growth & Launch Products. The company has raised its full-year forecasts and Management Guidance due to better-than-expected performance in the first half, including less impact from generic competition for VYVANSE® in the U.S. and updated foreign exchange predictions.

Takeda, based in Osaka, Japan, and Cambridge, Massachusetts, has announced that the Japanese Ministry of Health, Labour and Welfare has approved its FRUZAQLA Capsules (1mg/5mg), which contain the active ingredient fruquintinib. This medication is a selective oral inhibitor targeting vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3. It is intended for patients with advanced or recurrent colorectal cancer that cannot be cured or surgically removed and has worsened after chemotherapy.

Investors looking at stocks in the Medical - Drugs sector may be familiar with Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). However, which of these two stocks is more appealing for value investors?